Last updated: July 17, 2026

Application No. 18/832,464

INJECTABLE FORMULATION CONTAINING ISOXAZOLINE DERIVATIVE

Non-Final OA

Filed

Jul 23, 2024

Priority

Jan 24, 2022 — RE 10-2022-0010141 +1 more

Examiner

BAZARGANI, ARYA AHMADI

Art Unit

Tech Center

Assignee

LG Chem Ltd.

OA Round

1 (Non-Final)

Interview Optional

— +0.0% interview lift. Interview lift (+0.0%) is below the 15.0% threshold. A written response is recommended.

Based on 3 resolved cases, 2023–2026

Examiner Intelligence

BAZARGANI, ARYA AHMADI View full profile →

Grants 67% — above average

Career Allowance Rate

2 granted / 3 resolved

+6.7% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 4m

Avg Prosecution

30 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

72.6%

+32.6% vs TC avg

§112

11.0%

-29.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 3 resolved cases

Prosecution Timeline

Jul 23, 2024

Application Filed

May 20, 2026

Non-Final Rejection mailed (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

67%

Grant Probability

67%

With Interview (+0.0%)

2y 4m (~4m remaining)

Median Time to Grant

Low

PTA Risk

Based on 3 resolved cases by this examiner. Grant probability derived from career allowance rate.